Daniel Getts
Fondateur chez Myeloid Therapeutics, Inc.
Profil
Daniel Getts is the founder of Myeloid Therapeutics, Inc. (founded in 2019) and serves as the Chief Executive Officer & Director.
Dr. Getts is also the founder of Cour Pharmaceuticals Development Co., Inc. Dr. Getts's current job is as a Director at Curate Biosciences since 2022.
Dr. Getts's former job includes being a Director of Research & Development at Tolera Therapeutics, Inc. Dr. Getts also served as the Vice President of Research at TCR2 Therapeutics, Inc. from 2017 to 2019.
Dr. Getts has a doctorate degree from Northwestern University and graduate and doctorate degrees from The University of Sydney.
Postes actifs de Daniel Getts
| Sociétés | Poste | Début |
|---|---|---|
Myeloid Therapeutics, Inc.
 Myeloid Therapeutics, Inc. BiotechnologyHealth Technology Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA. | Fondateur | 01/01/2019 |
Curate Biosciences
 Curate Biosciences Miscellaneous Commercial ServicesCommercial Services Curate Biosciences engages in the development of a liquid biopsy platform for obtaining rare circulating tumor cells. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company was founded by Michael D. Grisham in 2002 and is headquartered in Richmond, VA. | Directeur/Membre du Conseil | 15/08/2022 |
Anciens postes connus de Daniel Getts
| Sociétés | Poste | Fin |
|---|---|---|
| TCR2 THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 01/03/2019 |
Cour Pharmaceuticals Development Co., Inc.
 Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Fondateur | - |
Tolera Therapeutics, Inc.
 Tolera Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tolera Therapeutics, Inc. develops novel therapies and technologies for immune modulation. Its products include anti-aßTCR antibody an immune induction therapy in solid organ transplantation and graft versus host disease. The company was founded by Jake Orville, Maria Siemionow, James J. Herrmann and John J. Puisis in 2007 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - |
Formation de Daniel Getts
| Northwestern University | Doctorate Degree |
| The University of Sydney | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Tolera Therapeutics, Inc.
Tolera Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tolera Therapeutics, Inc. develops novel therapies and technologies for immune modulation. Its products include anti-aßTCR antibody an immune induction therapy in solid organ transplantation and graft versus host disease. The company was founded by Jake Orville, Maria Siemionow, James J. Herrmann and John J. Puisis in 2007 and is headquartered in Ann Arbor, MI. | Commercial Services |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Myeloid Therapeutics, Inc.
Myeloid Therapeutics, Inc. BiotechnologyHealth Technology Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA. | Health Technology |
Cour Pharmaceuticals Development Co., Inc.
Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Health Technology |
Curate Biosciences
Curate Biosciences Miscellaneous Commercial ServicesCommercial Services Curate Biosciences engages in the development of a liquid biopsy platform for obtaining rare circulating tumor cells. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company was founded by Michael D. Grisham in 2002 and is headquartered in Richmond, VA. | Commercial Services |
